RxDoctor Payments DataLook up a doctor →

Jeremiah Lowney, DO

Family Medicine · Hyde Park, MANPI 1164576138

Payments from drug & device makers

$16,673in general payments, 2019–2025

Across 805 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • AbbVie$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • plus $7K from 42 others

What the payments were for

  • Food & beverage$16,659100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,673 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$183,682
Medicare patients
270
Services billed
2,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$109,811
FarxigaDapagliflozin Propanediol51$68,050
OzempicSemaglutide44$53,185
BiktarvyBictegrav/Emtricit/Tenofov Ala52$47,416
JardianceEmpagliflozin31$44,641
TrulicityDulaglutide21$33,216
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$32,138
JanuviaSitagliptin Phosphate12$17,237
MounjaroTirzepatide13$13,684
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$10,221
Atorvastatin Calcium487$4,396
Incruse ElliptaUmeclidinium Bromide11$3,834
Potassium Chloride45$2,361
Omeprazole166$2,239
Lidocaine13$2,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,320$109,811120 claims
AstraZenecaFarxiga$2,917$68,05051 claims
Novo NordiskOzempic$1,866$53,18544 claims
Lilly USA, LLCTrulicity, Mounjaro$1,154$46,90134 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$433$46,19374 claims
Boehringer IngelheimJardiance$1,143$44,64131 claims
MerckJanuvia$306$17,23712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Hyde Park

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →